List volumes - List articles in this issue

Investigative Report

Psoriasis May Not Be an Independent Predictor for the Use of Cardiovascular and Anti-diabetic Drugs: A 5-year Prevalence Study

doi: 10.2340/00015555-0688


Most studies investigating the association between psoriasis and cardiovascular disease have shown a significant relationship. This comparison study investigated the association between psoriasis and prevalent use of cardiovascular drugs. Drug exposure data for 1998 to 2006 were extracted from the Dutch PHARMO-Record Linkage System database. Psoriasis patients were selected using an algorithm of hospitalization and drug dispensing records specific for psoriasis and matched with controls for gender, age and time-period. From the records of 2.5 million Dutch residents, 9,804 (0.4%) psoriasis patients and 15,288 (0.6%) controls were selected. Psoriasis patients used significantly more anti-hypertensives, anti-coagulant and anti-platelet agents, digoxin, nitrates, lipid-lowering and anti-diabetic drugs than the reference population during a 5-year period observation. In a multiple linear regression model adjusting for the number of unique drugs used, psoriasis was no longer significantly associated with any of these drug classes. Psoriasis patients used more cardiovascular-related drugs, but surveillance bias appears to affect this association considerably.


Marlies Wakkee, Willemijn Meijer, H.A. Martino Neumann, Ron M.C. Herings, Tamar Nijsten


  • McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 1973; 288: 912.
  • Warrington KJ, Kent PD, Frye RL, Lymp JF, Kopecky SL, Goronzy JJ, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 2005; 7: R984–R991.
  • Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722–732.
  • Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1–9.
  • Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271–276.
  • Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988; 91: 197–201.
  • Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999; 135: 1490–1493.
  • Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225–230.
  • Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–1741.
  • Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829–835.
  • Brauchli YB, Jick SS, Curtin F, Meier CR. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol 2008; 158: 1299–1307.
  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.
  • Alevizos A, Larios G, Mariolis A. Psoriasis and risk of myocardial infarction. JAMA 2007; 297: 361; author reply 362–363.
  • Wakkee M, Nijsten T. Comorbidities in dermatology. Dermatol Clin 2009; 27: 137–147.
  • Conen D, Martina B, Perruchoud AP, Leimenstoll BM. High prevalence of newly detected hypertension in hospitalized patients: the value of inhospital 24-h blood pressure measurement. J Hypertens 2006; 24: 301–306.
  • Bohler S, Scharnagl H, Freisinger F, Stojakovic T, Glaesmer H, Klotsche J, et al. Unmet needs in the diagnosis and treatment of dyslipidemia in the primary care setting in Germany. Atherosclerosis 2007; 190: 397–407.
  • de Torbal A, Boersma E, Kors JA, van Herpen G, Deckers JW, van der Kuip DA, et al. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J 2006; 27: 729–736.
  • PHARMO, Institute for drug outcome research [cited 2009 March 24]. Available from: URL:
  • Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619–625.
  • Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14: 795–803.
  • WHO: WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo: WHO, 1999.
  • WHO: WHO. International Classification of Diseases, 9th revision, clinical modification, and HIV infection codes addendum (rev. nr. 1). Geneva: WHO, 1987.
  • Lamberts H, Wood M (editors). ICPC. International Classification of Primary care. Oxford: Oxford University Press, 1987.
  • Spuls PI, Bossuyt PM, van Everdingen JJ, Witkamp L, Bos JD. The development of practice guidelines for the treatment of severe plaque form psoriasis. Arch Dermatol 1998; 134: 1591–1596.
  • Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007; 25: 606–615.
  • Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 2007; 167: 847–852.
  • Gumbs PD, Verschuren WM, Mantel-Teeuwisse AK, de Wit AG, Hofman A, Trienekens PH, et al. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study. Drugs Aging 2006; 23: 733–741.
  • Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136–139.
  • Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol 2005; 141: 19–26.
  • Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506–509.
  • Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 1986; 172: 298–304.
  • Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61–67.
  • Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses’ Health Study II. Arch Intern Med 2007; 167: 1670–1675.
  • Related articles

    There are no related articles.

    Share with your friends



    Full text



    There is no supplementary for this article.

    Print information

    Volume 89, Issue 5

    DOI: 10.2340/00015555-0688

    Pages: 476-483

    View at PubMed